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DiarylpyrrolesWe report the synthesis and bio-pharmacological evaluation of a class of pyrrole derivatives featuring a
small appendage fragment (carbaldehyde, oxime, nitrile) on the central core. Compound 1c proved to be
extremely effective in vivo, showing an interesting anti-nociceptic proﬁle that is comparable to reference
compounds already marketed, hence representing a great stimulus for a further improvement of this
class of molecules.
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Nonsteroidal anti-inﬂammatory drugs (NSAIDs) represent a
chemically heterogeneous class of drugs which effectively reduce
inﬂammation and relieve pain.1 NSAIDs efﬁcacy is related to their
inhibitory effects towards cyclooxygenase (COX)-2-dependent
prostanoids in inﬂamed peripheral tissues and in central nervous
systems, such as spinal cord.2
However, variabilities in the analgesic and anti-inﬂammatory
responses to NSAIDs have been detected, and it has been suggested
that these variabilities are linked to both pharmacodynamic and
pharmacokinetic features (i.e., the extent and duration of COX-2
inhibition at therapeutic plasma concentrations).3 Approximatelyone third of the COX-2 selective inhibition attained by selective
NSAIDs (named coxibs: such as rofecoxib and celecoxib), has been
shown to be dependent on genetic sources of variance, for exam-
ple, polymorphisms COX-1 and CYP2C9.4 Both traditional NSAIDs
(tNSAIDs) and coxibs are associated with a small, but consistent,
increased risk of serious adverse events in the cardiovascular sys-
tem while tNSAIDs are endowed with enhanced risk of upper gas-
trointestinal bleeding.5,6 The degree of COX-2 selectivity assessed
in vitro may predict enhanced cardiovascular hazard while that
of COX-1 may predict the gastrointestinal toxicity.5–7 However,
other determinants may inﬂuence the hazards associated with
the use of NSAIDs in patients, such as pharmacokinetic features
(i.e., t1/2), administered doses and genetic background.5,8,9 In our
continuing research program aimed at developing novel anti-
inﬂammatory agents, we reported several studies on the design,
synthesis and activity of pyrrole-based COX-2 inhibitors.10–22
Structure–activity relationships of these compounds underlined
the side chain as a crucial parameter for activity.
In order to further analyse the relationship between side-chain
dimension and activity/selectivity, we became interested in the
work by Khanna et al. describing the synthesis and biological eval-
uation of several pyrrole-based compounds, characterised by the
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Figure 1. Structures of diphenyl pyrroles 1a–d, 2a–d and 3a–d.
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achieving a deeper knowledge on this class of small-side-chained
compounds, we synthesised aldehydes 1a–d, oximes 2a–d and ni-
triles 3a–d as potential tools for further developing the anti-
inﬂammatory agents armamentarium (Fig. 1).
2. Results and discussion
2.1. Synthesis
The synthesis commenced with a Stetter umpolung between
4-methythiobenzaldehyde and methyl vinyl ketone, followed by
oxidation of the sulfur by means of Oxone; the pyrrole core
was obtained through a Paal–Knorr condensation (Scheme 1).10O
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Table 1
In vitro COX-1 and COX-2 inhibitory activities of 1a–d, 2a–d and 3a–d and celecoxib
Compound R IC50 (COX-1)c (lM)
1aa 4-F >10
1b 3-F >10
1c 3,4-F2 >10
1d –H >10
2a 4-F >10
2b 3-F >10
2c 3,4-F2 >10
2d –H >10
3ab 4-F >10
3b 3-F >10
3c 3,4-F2 >10
3d –H >10
Celecoxib – 3.84
a Khanna et al. reported 3.23 lM (IC50) towards COX-2 isoform.
b Khanna et al. reported 0.75 lM (IC50) towards COX-2 isoform. In both cases Khanna
COX-1 and COX-2.
c Results are expressed as the mean (n = 3 experiments) of the percentage inhibition o
values were calculated by GraphPad Instat program; data ﬁt was obtained using the sig
d In vitro COX-2 selectivity index [IC50 (COX-1)/IC50(COX-2)].Compounds 1a–d were obtained in good yields and good regiose-
lectivity (formation of the C4 regioisomer ranging from 2% to 5%
determined on the crude material by 1H NMR) via selective
C3-formylation using the Vilsmeier’s reagent (the regiochemistry
of substitution was established by NOE studies). The material ob-
tained was of sufﬁcient puriprty to progress the synthesis through
the next stage. Synthesis of oximes 2a–d was accomplished by
reacting carboxaldehydes 1a–d with hydroxylamine chloride in
the presence of sodium acetate in ethanol/water. After reﬂuxing
the mixture for one and a half hour, cooling down the reaction
mixture caused precipitation of the oximes 2a–d as white ﬁne
crystalline materials that could be isolated in very good yields.
Dehydration of oximes to nitriles 3a–d was achieved by reacting
oximes 2a–d with a solution of 2,4,6-trichloro[1,3,5]triazine in
dimethylformamide for 8 h.24 Chromatographic puriﬁcation, fol-
lowed by recrystallization gave target compounds 3a–d.2.2. Biological and pharmacological studies
All the compounds were tested in vitro at different concentra-
tions up to 10 lM, to assess their inhibitory activities towards both
cyclooxygenases (COX-1 and COX-2) expressed in the murine
monocyte/macrophage J774 cell line. Compound selectivity toward
COX-2, referred to as selectivity index (SI), is deﬁned as the ratio ofR
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f title compounds.
IC50 (COX-2)c (lM) COX-1/COX-2d (SI)
0.0340 >294.1
0.0095 >1052.6
0.0700 >142.8
0.0340 >294.1
0.3600 >27.8
0.4400 >22.7
0.1600 >62.5
0.1900 >52.6
0.0290 >344.8
0.0130 >769.2
0.0022 >454.5
0.3600 >27.8
0.0610 62.9
performed the experiment by testing compounds 1a and 3a against puriﬁed human
f PGE2 production by test compounds with respect to control samples and the IC50
moidal dose–response equation (variable slope) (GraphPad software).
C. Battilocchio et al. / Bioorg. Med. Chem. 21 (2013) 3695–3701 3697the concentration required to inhibit the activity of both isoen-
zymes by 50% (COX-1/COX-2 IC50 ratio).
All compounds did not affect J774 COX-1 activity and this may
be related to the fact that the assay was performed in the presence
of high concentrations of free arachidonic acid (AA), which may in-
duce a cooperative activation of COX-1, thereby possibly reducing
the potency of the compounds.25 In contrast, all the compounds
inhibited J774 COX-2 activity with varying potencies. In particular,
these results indicate that the introduction of a ‘small’ lateral chain
installed on the pyrrole core is indeed suitable for ﬁne-tuning the
interactions with the biophase (Table 1). Though aldehydes 1a–d,
as well as nitriles 3a–c, showed a higher degree of inhibition, there
is not a unique trend related to the substitution pattern as such. In
particular, aldehyde 1b and nitrile 3c proved to be the most potent
derivatives towards J774 COX-2, showing IC50 values of 9.5 nM,
and 2.2 nM, respectively and being 8- and 36-fold more potent
than celecoxib used as control. On the contrary, oximes 2a–d, as
well as nitrile 3d, proved to be less active at inhibiting J774 COX-2.
The analgesic activities of the compounds were evaluated
in vivo, measuring the reduction of writhes induced by intra-peri-
toneal injections of acetic acid solution in mice, a model of inﬂam-
matory pain.26 Each compound was orally administered (po)
(1–40 mg kg1 dose range) 30 min before the induction of writhes.
Results are reported as number of writhes and as percentage of
writhes reduction with respect to vehicle-treated mice in Table 2.
Aldehyde 1c showed both the best efﬁcacy and potency inducing a
percentage of writhes reduction comparable to that of celecoxib.
Interestingly, both 1c and celecoxib also showed similar potencies
at inhibiting COX-2 in vitro. In particular, compound 1cwas signif-
icantly active even when dosed at 1 mg kg1 (36% reduction) and it
was able to reduce writhes by 60% after administration at
40 mg kg1; moreover, animals treated with compound 1c showed
a constant response of writhe reduction (about 50%) with absence
of dose dependency within the range of 5–20 mg kg1.Table 2
Effect of 1a–d, 2a–d, 3a–d, celecoxib, and vehicle (CMC) in the mouse abdominal constric
Number of writhes (%
Compound CMC 1 mg kg1 (%) 5 mg kg1 (%)
CMC 33.4 ± 2.5 –– ––
1a –– nd 31.7 ± 3.6
(5)
1b –– nd 33.4 ± 3.1
()
1c –– 21.3 ± 2.8* 16.7 ± 3.1*
(36) (50)
1d –– nd 33.0 ± 2.8
()
2a –– nd 32.6 ± 2.7
(2)
2b –– nd 33.1 ± 4.0
()
2c –– nd 30.2 ± 4.0
(10)
2d –– nd 28.9 ± 2.7
(13)
3a –– nd 29.8 ± 2.8
(5)
3b –– nd 26.4 ± 3.1
(21)
3c –– nd 30.7 ± 2.5
(8)
3d –– nd 35.4 ± 3.3
()
Celecoxib –– 19.3 ± 2.5* 16.6 ± 2.2*
(42) (50)
All compounds were suspended in 1% CMC and per os (po) administered 30 min before th
of 10 mice.
^ P < 0.05.
* P < 0.01 in comparison with CMC treated group.It is worth mentioning that oximes 2a, 2b and 2d showed a sim-
ilar constant dose response (ranging from 41% to 57%) when
administered at higher dose range (20–40 mg kg1).
Finally, at 40 mg kg1 doses, nitriles 3c and 3d, proved to be
able to reduce the writhes by 57% and 59%, respectively, while
3a and 3b were only moderately active (about 45% and 38% of
writhe reduction, respectively).
Surprisingly, some of the most in vivo effective compounds
(e.g., 2a, 2b, 2d, and 3d) did not show the best results in the corre-
sponding in vitro test. The good in vivo efﬁcacy of these com-
pounds may suggest a high in vivo metabolism with respect to
1a, 1b, 1d, 2c as well as 3b showing higher potencies towards
COX-2. In addition, differences in protein binding properties
among compounds 1–3, might contribute to different in vivo
effects.
All the compounds proved to inhibit J774 COX-2 activity
in vitro, and this inhibitory effect is reasonably involved in their
analgesic and anti-inﬂammatory activities detected in vivo.
As discussed above, assessment of selectivity towards COX-2
using the J774 cell-based assay cannot be considered the best
way to assess the extent of COX-2 selectivity achieved in vivo after
dosing the compounds, due to the high concentrations of free AA.
Therefore, we studied the COX-2 selective inhibition of three rep-
resentative compounds––aldehyde 1c, oxime 2c and nitrile 3b––
by using the human whole blood (HWB) assay for COX-1 and
COX-2.27,28 This assay can give information about the inhibitory ef-
fects of compounds towards human platelet COX-1 activity, a clin-
ically relevant target related to the gastrointestinal side-effects of
NSAIDs;6 it can also give information about human monocyte
COX-2 activity induced in response to inﬂammatory stimulus, such
as lipopolysaccharide (LPS), which is a clinically relevant target re-
lated to the anti-inﬂammatory activity. The assay was performed
to predict the actual extent of isozyme inhibition achievable
in vivo by circulating drug levels to consider the amount of variablestion test (acetic acid 0.6%)
writhe reduction)
10 mg kg1 (%) 20 mg kg1 (%) 40 mg kg1 (%)
–– –– ––
33.6 ± 3.7 23.3 ± 2.9 22.9 ± 3.0
() (30) (31)
20.3 ± 2.2* 18.8 ± 3.4* nd
(39) (44)
15.8 ± 2.8* 16.1 ± 2.9* 13.3 ± 2.3*
(53) (52) (60)
25.8 ± 3.0^ 22.8 ± 3.1* 23.2 ± 2.2*
(23) (32) (30)
21.5 ± 3.2* 19.8 ± 2.5* 17.8 ± 2.9*
(36) (41) (47)
22.6 ± 3.5* 19.2 ± 1.7* 18.2 ± 1.7*
(32) (42) (45)
27.1 ± 2.3 24.3 ± 3.2^ nd
(19) (27)
24.5 ± 3.4^ 15.6 ± 2.5* 14.8 ± 3.1*
(27) (53) (57)
21.3 ± 2.7* 22.5 ± 3.1* 18.2 ± 3.0*
(36) (33) (45)
23.9 ± 2.8^ 22.5 ± 3.1* 20.7 ± 2.6*
(28) (33) (38)
26.9 ± 3.0 20.6 ± 3.0* 14.2 ± 2.5*
(19) (38) (57)
24.1 ± 2.3* 19.3 ± 2.8* 13.8 ± 2.9*
(28) (42) (59)
14.2 ± 2.3* 13.9 ± 2.7* 10.2 ± 2.1*
(57) (58) (69)
e experiment. 0.6% acetic acid was administered ip. Each value represents the mean
Figure 2. Effects of the compounds 1c, 2c and 3b on COX-1 and COX-2 activity in HWB. Concentration-response curves for inhibition of whole blood COX-1 activity were
assessed by measuring serum thromboxane (TX) B2 levels by the compounds 1c (A), 2c (B), and 3b (C) (0.1–1000 lM). Results were reported as percentage of inhibition
(mean ± SEM) from three separate experiments. Concentration-response curves for inhibition of whole blood COX-2 induced by LPS (10 lg/ml) were assessed by measuring
PGE2 levels by the compounds 1c (0.1–300 lM) (A), 2c (0.01–300 lM) (B), and 3b (0.001–300 lM) (C). Results were reported as percentage inhibition (mean ± SEM) from
three separate experiments. Open red symbols represent COX-2 inhibition. Closed black symbols represent COX-1 inhibition. Red and black lines represent the concentration-
response curves for inhibition of COX-2 and COX-1, respectively, by the compounds 1c, 2c and 3b in vitro.
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ure 2, compounds 1c, 2c and 3b inhibited LPS-induced whole blood
PGE2 generation (COX-2 assay), in a concentration-dependent fash-
ion with IC50 values of 14.8 [95% conﬁdential interval (CI), 10.3–
21.4] lM, 17.3 (95% CI, 8–41) lM, and 1.30 (95% CI, 0.72–2.5) lM,
respectively. In this assay, celecoxib showed an IC50 value of 0.39
(95% CI, 0.29–0.53) mM.5 All the tested compounds proved to be
more potent at inhibiting COX-2 than COX-1. Aldehyde 1c, oxime
2c and nitrile 3b proved to be 4.8-, 9.3- and 38.8-foldmore selective
towards COX-2, respectively. Nitrile 3b proved to be themost selec-
tive and potent one towards COX-2. Under the same experimental
conditions, celecoxib inhibited COX-1 with an IC50 value of 12.53
(95% CI, 8.67–17.90) mM, thus showing a COX-1/COX-2 IC50 ratio
of 30. Compound 3b hence showed selective activity comparable
to celecoxib towards COX-2. These results, even if referred to only
one example of each class of synthesized compounds, indicate that
nitrile derivatives show a better selectivity towards COX-2 than
the other two classes of derivatives. On the contrary, the little reduc-
tion of the analgesic efﬁcacy showed in vivo by nitriles with respect
to aldehyde 1c, might be related to reduced bioavailability, metabo-
lism and/or tissue distribution of nitriles. Whether improved COX-2
selectivity of nitrile derivatives might be associated with a better
gastrointestinal proﬁle, it requires to be assessed in vivowith appro-
priate experimental models.
3. Conclusions
Inspired by the work by Khanna et al. we managed to synthe-
size a class of diarylpyrroles which has been evaluated both biolog-
ically and pharmacologically. The results clearly suggest that
further modiﬁcation of the structure is needed to improve the
bio-pharmacological proﬁle of these molecules; nonetheless, alde-
hyde 1c proved to possess an outstanding anti-nociceptive activity
comparable to celecoxib. Oximes 2 showed interesting proﬁles, but
an isosteric replacement of the oxime moiety (in order to generate
a geometrical differentiation) is needed to evaluate any steric ef-
fect on the interaction with the biological receptor. Further studies
are on-going to bring about structural modiﬁcation in order to
undisclose the real potential of this kind of scaffold.
4. Materials and methods
4.1. Chemistry
1H NMR spectra were recorded with a Bruker Avance DPX-400
spectrometer with the residual solvent peak as the internal refer-
ence (CDCl3 = 7.26 ppm, DMSO-d6 = 2.50 ppm). 1H resonances arereported to the nearest 0.01 ppm. 13C NMR spectra were recorded
with the same spectrometers with the central resonance of the sol-
vent peak as the internal reference (CDCl3 = 77.16 ppm, DMSO-
d6 = 39.52 ppm). All 13C resonances are reported to the nearest
0.1 ppm. The multiplicity of 1H signals are indicated as: s = singlet,
d = doublet, m = multiplet, or combinations of thereof. Infrared
spectra were recorded neat on a Perkin–Elmer spectrum one FTIR
spectrometer using Universal ATR sampling accessories. Letters
in parentheses refer to the relative absorbency of the peak:
w = weak, less than 40% of the most intense peak; m = medium,
ca. 41–69% of the most intense peak; s = strong, greater than 70%
of the most intense peak. Mass spectra were recorded on a API-
TOF Mariner by Perspective Biosystem (Stratford, Texas, USA). Pur-
ity of compounds was assessed with elemental analysis obtained
by a PE 2400 (Perkin–Elmer) analyzer. Purity of target compounds
was >95%. Unless stated otherwise, reagents were obtained from
commercial sources and used without puriﬁcation. Unless other-
wise stated, heating was conducted using standard laboratory
apparatus. TLC analysis was performed on Merck 60 F254 silica
gel plates and visualized using both short and long waved ultravi-
olet light in combination with standard laboratory stains such as
acidic potassium permanganate. Melting points were performed
on either a Stanford Research Systems MPA100 (OptiMelt) auto-
mated melting point system or a Gallenkamp melting point ma-
chine and are uncorrected.
Synthesis of 1-[4-(methylthio)phenyl]pentane-1,4-dione (5). A
solution of 4-methylthiobenzaldehyde 4 (11.97 mL, 0.09 mol), tri-
ethylamine (19.5 mL, 0.14 mol), methyl vinyl ketone (5.8 mL,
0.09 mol), and 3-ethyl-5-(2-hydroxyethyl)-4-methylthiazolium
bromide (3.53 g, 0.014 mol), in a 20 mL vial, was microwave irradi-
ated using a CEM apparatus for 15 min at 70 C (150 W, internal
pressure of 150 psi). The reaction mixture was treated with 2 N
HCl (10 mL) and extracted with ethyl acetate; the organic layer
was washed with aqueous sodium bicarbonate and brine. The or-
ganic fractions were dried over sodium sulfate, ﬁltered, and con-
centrated to give an orange liquid which was crystallized from
cyclohexane to give intermediate 5 as white needles (80% yield).
ESI-mass: m/z 245.063 [M+Na]+, mp, and 1H NMR spectrum were
consistent with those reported in the literature.16,23
Synthesis of 1-[4-(methylsulfonyl)phenyl]pentane-1,4-dione
(6). To a solution of 5 (7.8 g, 35 mmol) in methanol (150 mL), a
solution of oxone (37.7 g, 61.4 mmol) in water (150 mL) was added
over 5 min. After being stirred at 25 C for 2 h, the reaction mixture
was diluted with water (400 mL) and extracted with dichlorometh-
ane. The organic layer was washed with brine (200 mL) and dried
(Na2SO4). After ﬁltration and concentration, the crude material
was chromatographed (silica gel, 3:1 hexane/ethyl acetate) to give
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and 1H NMR spectrum were consistent with those reported in
literature.16,23
General procedure for the synthesis of diarylpyrroles (7a–d).
Following the procedure for the Paal–Knorr reaction, a solution
of 6 (0.58 g, 2.28 mmol), the opportune aniline (2.28 mmol) and
p-toluenesulfonic acid (30 mg, 0.17 mmol) in ethanol (2 mL) was
microwave irradiated using a CEM apparatus for 45 min at 160 C
(150 W, internal pressure of 150 psi). The reaction mixture was
cooled and concentrated. The crude material was puriﬁed by chro-
matography on aluminum oxide with a 3:1 cyclohexane/ethyl ace-
tate mixture, as the eluant, to give the expected 1,5-diarylpyrrole 7
as white needles in satisfactory yield.
1-(4-Fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)-
1H-pyrrole (7a). ESI-mass: m/z 352.083 [M+Na]+, mp, and 1H NMR
spectrum were consistent with those reported in literature.16,23
1-(3-Fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)-
1H-pyrrole (7b). ESI-mass: m/z 352.091 [M+Na]+, mp, and 1H NMR
spectrum were consistent with those reported in literature.16,23
1-(3,4-Diﬂuorophenyl)-2-methyl-5-(4-methylsulfonyl)phenyl)-
1H-pyrrole (7c). ESI-mass: m/z 370.075 [M+Na]+, mp, and 1H NMR
spectrum were consistent with those reported in literature.16,23
2-Methyl-5-(4-(methylsulfonyl)phenyl)-1-phenyl-1H-pyrrole
(7d). ESI-mass: m/z 334.092 [M+Na]+, mp, and 1H NMR spectrum
were consistent with those reported in literature.16,23
General procedure for the synthesis of pyrrole-3-carbaldehy-
des (1a–d). To a solution of dimethylformamide (8.3 mmol) in
dichloromethane (10 mL) at 0 C, in a round-bottomed ﬂask
equipped with a stirring bar, phosphoryl chloride (8.4 mmol)
was added dropwise. After 30 min a solution of 7 (3.2 mmol in
10 mL of 100 dichloromethane) was added over 3 min and then
reﬂuxed for 1 h. The reaction mixture was cooled down to rt, di-
luted with saturated carbonate solution (50 mL) and extracted
with dichloromethane. The organic layer was washed with brine
(200 mL) and water (200 mL) and dried over sodium sulfate.
After ﬁltration and concentration, the crude material was crystal-
lized using ethyl acetate to give the aldehyde as an off-white
solid.
2-Methyl-5-[4-(methylsulfonyl)phenyl]-1-[4-ﬂuoro-phenyl]-
1H-pyrrole-3-carboxaldehyde (1a). White needles (>95% yield).
ESI-mass:m/z 357,082 [M+Na]+; Elem. Anal. for C19H16FNO3S calcd
C, 63.85; H, 4.51; N, 3.92. Found C, 63.82; H, 4.55; N, 3.98; data, mp,
1H and 13C NMR spectra were consistent with those reported in the
literature.23
2-Methyl-5-[4-(methylsulfonyl)phenyl]-1-[3-ﬂuoro-phenyl]-
1H-pyrrole-3-carboxaldehyde (1b). Off-white needles (>95% yield),
mp 170 C. FT-IR (neat, cm1) v: 2770 (w), 1673 (s), 1590 (s), 1506
(s), 1300 (s), 1140 (s); 1H NMR (DMSO-d6 400 MHz) ppm: 9.93 (s,
1H), 7.85 (m, 1H), 7.52 (m, 1H), 7.40 (m, 2H), 7.31 (m, 1H,
J = 8.6 Hz), 7.08 (d, 2H, J = 8.6 Hz), 6.94 (s, 1H), 3.17 (s, 3H), 2.37
(s, 3H). 13C NMR (CDCl3 100 MHz) ppm: 187.09, 163.43, 142.70,
138.91, 138.11, 137.00, 131.54, 128.84, 128.55, 117.40, 117.02,
116.03, 112.03, 107.02, 106.82, 44.33, 10.89; ESI-mass: m/z
380.073 [M+Na]+; Elem. Anal. for C19H16FNO3S calcd C, 63.85; H,
4.51; N, 3.92. Found C, 63.80; H, 4.57; N, 3.95.
2-Methyl-5-[4-(methylsulfonyl)phenyl]-1-[3,4-diﬂuoro-phe-
nyl]-1H-pyrrole-3-carboxaldehyde (1c). Off-white needles
(>95%yield), mp 178 C. FT-IR (neat, cm1) v: 2785 (w), 1671 (s),
1592 (s), 10 1500 (s), 1304 (s), 1133(s); 1H NMR (CDCl3
400 MHz) ppm: 9.97 (s, 1H), 7.77 (m, 3H), 7.55 (m, 1H), 7.36 (d,
2H, J = 8.7 Hz), 7.22 (m, 1H), 6.98 (s, 1H), 3.20 (s, 3H), 2.39 (s,
3H). 13C NMR (CDCl3 100 MHz) ppm: 187.09, 163.03, 150.31,
140.70, 138.90, 138.10, 137.09, 131.50, 128.93, 128.59, 118.03,
117.33, 15 109.22, 108.8, 107.02, 44.39, 10.99; ESI-mass: m/z
398.064 [M+Na]+; Elem. Anal. for C19H15F2NO3S calcd C, 60.79; H,
4.03; N, 3.73. Found C, 61.00; H, 3.99; N, 3.78.2-Methyl-5-[4-(methylsulfonyl)phenyl]-1-phenyl-1H-pyrrole-
3-carboxaldehyde (1d). Off-white needles (>95%yield), mp 160 C.
FT-IR (neat, cm1) v: 2782 (w), 1679 (s), 1588 (s), 1503 (s), 1298
(s), 1106 (s); 1H NMR (CDCl3 400 MHz) ppm: 10.00 (s, 1H), 7.73
(d, 2H, J = 8.6 Hz), 7.46 (m, 3H), 7.22 (d, 2H, J = 8.6 Hz), 7.16 (m,
2H), 6.95 (s, 1H), 3.02 (s, 3H), 2.40 (s, 3H). 13C NMR (CDCl3
100 MHz) ppm: 186.69, 161.30, 140.30, 139.33, 138.04, 135.89,
133.70, 129.04, 128.55, 128.44, 125.40, 111.10, 109.57, 44.20,
11.44. ESI-mass: m/z 362.083 [M+Na]+; Elem. Anal. for C19H17NO3S
calcd C, 67.25; H, 5.05; N, 4.13. Found C, 67.33; H, 5.00; N, 4.18.
General procedure for the synthesis of pyrrole-3-carboximes
(2a–d). To a solution of aldehyde 1 (1 mmol) in ethanol (5 mL),
hydroxylamine chloride water solution (1 mmol in 4 mL of water)
and sodium acetate (1 mmol) were added. The reaction was re-
ﬂuxed for 1 h and a half. At the end the precipitated formed was
ﬁltered and collected to give the oxime 2 as white powder.
2-Methyl-5-[4-(methylsulfonyl)phenyl]-1-[4-ﬂuoro-phenyl]-
1H-pyrrole-3-carboxime (2a). White powder (>95%yield). FT-IR
(neat, cm1) v: 3285 (w), 1596 (s), 1518 (s), 1307 (s), 1149 (s),
956 (s), 774 (s); 1H NMR (400 MHz, DMSO-d6): (ppm) 10.94 (s,
1H), 10.61 (s, 1H), 8.11 (s, 1H), 7.70 (d, 4H, J = 40 8.4 Hz), 7.42–
7.31 (m, 9H), 7.21 (d, 4H, J = 8.4 Hz), 6.74 (s, 2H), 3.15 (s, 6H),
2.13 (s, 6H); 13C NMR (CDCl3 100 MHz) ppm: 159.66, 148.20,
138.92, 138.11, 136.73, 135.19, 133.30, 128.81,128.50, 123.22,
117.13, 116.10, 106.98, 47.88, 10.96; ESI-mass: m/z 395.084
[M+Na]+; Elem. Anal. for C19H17FN2O3S calcd C, 61.29; H, 4.60; N,
7.52. Found C, 61.25; H, 4.64; N, 7.58.
2-Methyl-5-[4-(methylsulfonyl)phenyl]-1-[3-ﬂuoro-phenyl]-
1H-pyrrole-3-carboxime (2b). White powder (>95%yield). FT-IR
(neat, cm1) v: 3292 (w), 1590 (s), 1510 (s), 1297 (s), 50 1140
(s), 950 (s), 766 (s); 1H NMR (400 MHz, DMSO-d6) ppm: 10.98 (s,
1H), 10.65 (s, 1H), 8.14 (s, 1H), 7.78 (d, 4H, J = 8.6 Hz), 7.53–7.43
(m, 2H), 7.36–7.33 (m, 6H), 7.18 (d, 4H, J = 8.4 Hz), 6.77 (s, 2H),
3.19 (s, 6H), 2.19 (s, 6H). 13C NMR (CDCl3 100 MHz) ppm: 163.55,
149.00, 143.00, 138.88, 138.21, 55 135.20, 133.10, 131.00,
128.77, 128.43, 117.21, 117.10, 112.28, 107.28, 106.90, 47.99,
11.06. ESI-mass: m/z 395.084 [M+Na]+; Elem. Anal. for
C19H17FN2O3S calcd C, 61.29; H, 4.60; N, 7.52. Found C, 61.27; H,
4.63; N, 7.50.
2-Methyl-5-[4-(methylsulfonyl)phenyl]-1-[3,4-iﬂuorophe-
nyl]-1H-pyrrole-3-carboxime (2c). White powder (>95%yield). FT-
IR (neat, cm1) v: 3280 (w), 1582 (s), 1522 (s), 1300 (s), 1117(s),
943 (s), 760 (s); 1H NMR (400 MHz, DMSO-d6): (ppm) 10.98 (s,
1H), 10.66 (s, 1H), 8.14 (s, 1H), 7.79 (d, 4H, J = 8.5 Hz), 7.64–7.69
(m, 2H), 7.66 (m, 2H), 7.43–7.23 (m, 5H), 7.15 (m, 2H), 6.77 (s,
2H), 3.19 (s, 6H), 2.19 (s, 6H). 13C NMR (CDCl3 100 MHz) ppm:
153.35, 148.33, 146.30, 138.98, 138.56, 138.31, 135.10, 133.13,
128.87, 128.53, 118.61, 117.70, 117.44, 108.88, 106.89, 48.01,
11.12. ESI-mass: m/z 413.075 [M+Na]+; Elem. Anal. for
C19H16F2N2O3S calcd C, 58.45; H, 4.13; N, 7.18. Found C, 58.50; H,
4.10; N, 7.20.
2-Methyl-5-[4-(methylsulfonyl)phenyl]-1-phenyl-1H-pyrrole-
3-carboxime (2d). White powder (>95%yield). FT-IR (neat, cm1) v:
3280 (w), 1599 (s), 1520 (s), 1289 (s), 1167 (s), 75 955 (s), 770 (s);
1H NMR 400 MHz, DMSO-d6): (ppm) 10.92 (s, 1H), 10.59 (s, 1H),
8.10 (s, 1H), 7.68 (d, 4H, J = 8.6 Hz), 7.45–7.32 (m, 11H), 7.23 (d,
4H, J = 8.6 Hz), 6.76 (s, 2H), 3.10 (s, 6H), 2.15 (s, 6H). 13C NMR
(CDCl3 100 MHz) ppm: 148.23, 141.22, 138.98, 138.16, 135.11,
133.17, 129.43, 128.89, 128.63, 80 125.66, 121.65, 106.91,
117.24, 47.66, 11.02. ESI-mass: m/z 377.094 [M+Na]+; Elem. Anal.
for C19H18N2O3S calcd C, 64.39; H, 5.12; N, 7.90. Found C, 64.42;
H, 5.15; N, 7.88.
General procedure for the synthesis of pyrrole-3-carbonitriles
(3a–d). A solution of 2,4,6-trichloro[1,3,5]triazine (1 mmol) in
0.2 mL of dimethylformamide was stirred for 30 min at room
temperature. Carboxime 2 (1 mmol), dissolved in 1.5 mL of
3700 C. Battilocchio et al. / Bioorg. Med. Chem. 21 (2013) 3695–3701dimethylformamide, was added, and the reaction mixture was stir-
red at room temperature for 8 h. The reaction mixture was then di-
luted with water (2 mL), extracted with ethyl acetate (50  3 mL),
washed with saturated carbonate solution (50 mL), 1 N HCl
(50 mL) and brine (50 mL). After ﬁltration and concentration, the
crude mixture obtained was puriﬁed by chromatography on silica
gel with 4:1 cyclohexane/ethylacetate mixture as eluent, to give
3 as a white solid. Recrystallization from ethanol gave 3 as white
crystals.
2-Methyl-5-[4-(methylsulfonyl)phenyl]-1-[4-ﬂuoro-phenyl]-
1H-pyrrole-3-carbonitrile (3a). White needles (80% yield). ESI-
mass: m/z 377.073 [M+Na]+; Elem. Anal. for C19H15FN2O2S calcd
C, 64.39; H, 4.27, N, 7.90. Found C, 64.45; H, 4.30; N, 7.98; mp,
1H and 13C NMR spectra were consistent with those reported in
the literature.23
2-Methyl-5-[4-(methylsulfonyl)phenyl]-1-[3-ﬂuoro-phenyl]-
1H-pyrrole-3-carbonitrile (3b). White needles (76.8% yield), mp
219 C. FT-IR (neat, cm1): 2220 (w), 1600 (s), 1519 (s), 1320 (s),
1013 (s), 944 (s); 1H NMR (400 MHz, CDCl3): (ppm) 7.78 (d, 2H,
J = 8.4 Hz), 7.50–7.44 (m, 1H), 7.23 (d, 2H, J = 8.4 Hz), 105 6.99–
6.92 (m, 3H), 6.71 (s, 1H), 3.05 (s, 3H), 2.35 (s, 3H). 13C NMR (CDCl3
100 MHz) ppm: 159.59, 140.66, 138.94, 138.01, 137.50, 133.41,
129.23, 128.89, 128.56, 117.55, 117.39, 116.00, 111.25, 108.02,
106.77, 45.00, 11.21; ESI-mass: m/z 377.074 [M+Na]+; Elem. Anal.
for C19H15FN2O2S calcd C, 64.39; H, 4.27; N, 7.90. Found C, 64.42;
H, 4.26; N, 7.95.
2-Methyl-5-[4-(methylsulfonyl)phenyl]-1-[3,4-diﬂuoro-phe-
nyl]-1H-pyrrole-3-carbonitrile (3c). White needles (78.0% yield),
mp 220 C. FT-IR (neat, cm1) v: 2225 (w), 1605 (s), 1516 (s), 115
1300 (s), 1023 (s), 958 (s); 1H NMR (400 MHz, CDCl3): (ppm)
7.79 (d, 2H, J = 8.3 Hz), 7.29–7.25 (m, 1H), 7.21 (d, 2H, J = 8.3 Hz),
7.06–7.02 (m, 1H), 6.95–6.93 (m, 1H), 6.68 (s,1H), 3.05 (s, 3H),
2.30 (s, 3H). 13C NMR (CDCl3 100 MHz) ppm: 159.66, 146.76,
138.64, 138.38, 137.53, 132.91, 128.78, 128.77, 117.44, 116.60,
108.14, 107.00, 44.89, 11.11. ESI-mass: m/z 395.064 [M+Na]+;
Elem. Anal. for C19H14F2N2O2S calcd C, 61.29; H, 3.79; N, 7.52.
Found C, 61.35; H, 3.82; N, 7.58.
2-Methyl-5-[4-(methylsulfonyl)phenyl]-1-phenyl-1H-pyrrole-
3-carbonitrile (3d). White needles (79.3% yield), mp 197 C. FT-IR
(neat, cm1) v: 2215 (w), 1607 (s), 1510 (s), 1309 (s), 1019 (s),
950 (s); 1H NMR (400 MHz, CDCl3): (ppm) 7.45 (d, 2H, J = 8.4 Hz),
7.30 (m, 3H), 7.20 (m, 2H), 7.18 (d, 2H, J = 8.4 Hz), 6.70 (s, 1H),
3.05 (s, 3H), 2.19 (s, 3H). 13C NMR (CDCl3 100 MHz) ppm: 138.90,
138.51, 133.57, 133.09, 129.42, 129.68, 128.40, 128.44, 125.55,
121.13, 117.38, 112.05, 110.65, 44.80, 11.55. ESI-mass: m/z
359.083 [M+Na]+; Elem. Anal. for C19H16N2O2S calcd C, 67.84; H,
4.79; N, 8.33. Found C, 67.80; H, 4.81; N, 8.35.
4.2. Biology
In vitro study. The murine monocyte/macrophage J774 cell line
was grown in DMEM supplemented with 2 mM glutamine, 25 mM
HEPES, 100 U/mL penicillin, 100 lg/mL streptomycin, 10% fetal bo-
vine serum (FBS) and 1.2% Na pyruvate. Cells were plated in 24-
well culture plates at a density of 2.5  105 cells/mL or in
60 mm-diameter culture dishes (3  106 cells/3 mL/dish) and al-
lowed to adhere at 37 C in 5% CO2 for 2 h. Immediately before
the experiments, culture medium was replaced by fresh medium
without FBS and cells were stimulated as described.29 To evaluate
COX-1 activity, cells were pre-treated with test compounds (0.01–
10 lM) for 15 min and further incubated at 37 C for 30 min with
15 lM AA in order to activate the constitutive COX-1. At the end
of the incubation, the supernatants were collected for the measure-
ment of prostaglandin E2 levels by radioimmunoassay (RIA). On the
other hand, to evaluate COX-2 activity, cells were stimulated for
24 h with Escherichia coli lipopolysaccharide (10 lg/mL) to induceCOX-2, in the absence or presence of test compounds, at the con-
centrations previously reported. Celecoxib was utilized as refer-
ence compound for selectivity index. The supernatants were
collected for the measurement of PGE2 by RIA. Throughout the
time the experiments lasted, triplicate wells were used for the var-
ious conditions of treatment. Results are expressed as the mean, for
three experiments, of the percent inhibition of PGE2 production by
test compounds with respect to control samples. The IC50 values
were calculated by GraphPad Instat program, data ﬁt was obtained
using the sigmoidal dose–response equation (variable slope)
(GraphPad software).
In vitro HWB assay. Compounds 1c, 2c and 3b were evaluated
for COX-1 and COX-2 selectivity in HWB assays. Whole blood
was withdrawn from three healthy volunteers (age range
30 ± 3 years). Informed consent was obtained from each subject.
Compounds 1c, 2b and 3b were dissolved in DMSO, and 2 lL of
vehicle, or stock solution of the compounds were added to 1 mL
of whole blood to give ﬁnal concentrations of 0.001–1000 lM. To
evaluate COX-2 activity, 1 mL aliquots of peripheral venous
blood samples containing 10 IU of sodium heparin were incu-
bated in the absence or in the presence of LPS (10 lg/mL) (Sig-
ma–Aldrich, St. Louis, MO) with or without increasing
concentrations (0.001–300 mM) of the compounds (1c, 2b or
3b) for 24 h at 37 C.28 The contribution of platelet COX-1 was
suppressed by pretreating the subjects with 300 mg aspirin
48 h before sampling. PGE2, as an index of monocyte COX-2
activity, was measured in plasma by previously described and
validated RIAs.25 Moreover, peripheral venous blood samples
were drawn from the same donors when they had not taken
any NSAIDs during the 2 weeks preceding the study. Aliquots
(1 mL) of whole blood were immediately transferred into glass
tubes in the presence of vehicle (DMSO), or different concentra-
tions (0.1–1000 mM) of the compounds, and allowed to clot at
37 C for 1h. Whole blood TXB2, as a reﬂection of maximally
stimulated platelet COX-1 activity in response to endogenously
formed thrombin, was measured in serum by previously de-
scribed and validated RIA.27 For each experiment, the results
were reported as percentage of inhibition of PGE2 or TXB2 pro-
duction by test compounds with respect to control samples
(DMSO vehicle). The IC50 values were calculated by using Graph-
Pad Prism (version 5.00 for Windows, GraphPad).
4.3. Pharmacology
In vivo analgesic/anti-inﬂammatory study. Animal handling
was carried out according to the European community guidelines
for animal care (DL 116/92, application of the European Commu-
nities Council Directive 86/609/EEC). The ethical policy of the
University of Florence conforms with the Guide for the Care
and Use of Laboratory Animals of the U.S. National Institutes
of Health (NIH Publication No. 85–23, revised 1996; University
of Florence assurance number: A5278-01). Formal approval to
conduct the experiments described herein was obtained from
the animal subjects review board of the University of Florence.
For the experiment described male Swiss albino mice (23–25 g)
were used. The animals were fed with a standard laboratory diet
and tap water ad libitum, and kept at 23 ± 1 C with a 12 h light/
dark cycle, light on at 7 a.m. The analgesic/anti-inﬂammatory
activity of the new compounds was investigated in the mouse
abdominal constriction test.30 Mice, randomly distributed in dif-
ferent groups, were injected intraperitoneally (ip) with 0.6% ace-
tic acid and, 5 min later, the number of writhes due to
abdominal constriction was counted for further 10 100 min. All
compounds at the doses of 1, 5, 10, 20 and 40 mg kg1, or the
vehicle (1% carboxymethylcellulose) were administered per os
(po) 30 min before acetic acid injection.
C. Battilocchio et al. / Bioorg. Med. Chem. 21 (2013) 3695–3701 37014.4. Statistical analysis
Results were expressed as the means ± SEM and an analysis of
variance was performed by ANOVA. A Fisher’s protected least sig-
niﬁcant difference procedure was used as post-hoc comparison. P
values of less than 0.05 or 0.01 were considered signiﬁcant. Data
were analyzed using the ‘Origin 7.5’ software.
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